fda warning compounded semaglutide october 2025 Medscape | The has approved once-daily oral 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. FDA Decisions Expected: October 2025
Description
Third-party testing documentation and certificates of analysis help verify quality when sourcing research compounds
Once that date passes, semaglutide undergoes irreversible chemical degradation, and refrigeration does not reverse this process
The results of a trial of semaglutide in obese patients with HFpEF showed a significant amelioration of symptoms and improvements in motor function and weight loss compared with patients treated with a placebo
Your food environment also matters
Common methods include 16:8 fasting (16 hours fasting, 8-hour eating window) or alternate-day fasting
